Published May 19, 2017
Javier Blanco, associate professor, pharmaceutical sciences, has received a $400,000 R21 award from the National Institute of Child Health and Human Development.
Blanco is the principal investigator on the project titled “Epigenetic Regulation of FcRn Expression in Human Lung and its Role in the Disposition of Monoclonal Antibody Drugs."
The development of monoclonal antibody drugs (mAbs) has revolutionized clinical treatments for a wide variety of diseases. The studies in Blanco’s proposal promise to provide fundamental insights into the epigenetic control of mAbs trafficking in lung, the target organ for a novel class of inhaled mAbs.
“We anticipate that the findings derived from this project can be quickly incorporated into various platforms to design innovative therapeutic approaches with inhaled mAbs for the treatment of prevalent pulmonary diseases such as asthma, chronic obstructive pulmonary disease, and lung cancers,” Blanco says.